As of July 1, 2024, the Myrbetriq Patient Assistance Program is no longer accepting new patients or re-enrolling existing patients for Myrbetriq (a product used to relieve symptoms of overactive bladder). For uninsured patients currently enrolled, program enrollment date will end August 31, 2024 and December 31, 2024 for Medicare Part D patients. Samples of the brandname medication Gemtesa can be obtained by providers here. Generic options such as oxybutynin, fesoterodine and solifenacin are available from RxOutreach for low-cost fees based on product/quantity selected. Be sure to consult with a healthcare provider or pharmacist to discuss other suitable alternative options once eligibility ends for Myrbetriq.

Beginning in mid-July, Janssen’s Patient Assistance Program will be transitioning its pharmacy services from TC Script Pharmacy to Wegmans Specialty Pharmacy. For more information, contact Wegmans Specialty Pharmacy at 1-866-889-5660.

Beginning July 22, 2024, AbbVie’s Patient Assistance Program will require patients with Medicare Part D who are under 150% FPL to provide a proof of denial from the Medicare Low Subsidy (LIS) program before evaluation for Patient Assistance Program eligibility. This applies to medications that are reimbursed under a Medicare Part D prescription drug plan. AbbVie is encouraging Medicare patients who are under 150% FPL to apply to the Medicare Extra Help now to provide time to complete the enrollment process and avoid a lapse in therapy.

Patients can apply for Extra Help any time before or after enrollment in Medicare Part D. For more information or to apply, visit: https://www.medicare.gov/extrahelp.  

Have you seen other PAPs require this step as part of the enrollment process? We’ll share more information as it becomes available and at the Fall Roundtables in October!